

Annuska M Glas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2765952/publications.pdf>

Version: 2024-02-01

65
papers

13,838
citations

81743

39
h-index

110170

64
g-index

66
all docs

66
docs citations

66
times ranked

13047
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | <sc>MammaPrint</sc> and <sc>Blueprint</sc> comprehensively capture the cancer hallmarks in early-stage breast cancer patients. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 148-160. | 1.5 | 11 |
| 2 | Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1335-1345. | 0.8 | 28 |
| 3 | High concordance of 70-gene recurrence risk signature and 80-gene molecular subtyping signature between core needle biopsy and surgical resection specimens in early-stage breast cancer. <i>Journal of Surgical Oncology</i> , 2022, 125, 596-602. | 0.8 | 6 |
| 4 | 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. <i>Lancet Oncology</i> , The, 2021, 22, 476-488. | 5.1 | 179 |
| 5 | Controlling technical variation amongst 6693 patient microarrays of the randomized MINDACT trial. <i>Communications Biology</i> , 2020, 3, 397. | 2.0 | 7 |
| 6 | Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis. <i>International Journal of Cancer</i> , 2020, 147, 2303-2315. | 2.3 | 14 |
| 7 | Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and Blueprint® Kit at University Hospitals Leuven and Curie Institute Paris. <i>Translational Oncology</i> , 2019, 12, 1557-1565. | 1.7 | 6 |
| 8 | MammaPrint and Blueprint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 808-823. | 1.2 | 15 |
| 9 | Immunohistochemical versus molecular (Blueprint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 123-131. | 1.1 | 51 |
| 10 | Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, <i>BRCA1</i>-like status, tumor-infiltrating immune cells and survival. <i>Oncolmmunology</i> , 2018, 7, e1509820. | 2.1 | 80 |
| 11 | A breast cancer gene signature for indolent disease. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 461-466. | 1.1 | 19 |
| 12 | DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. <i>Npj Breast Cancer</i> , 2017, 3, 31. | 2.3 | 64 |
| 13 | A Computational Workflow Translates a 58-Gene Signature to a Formalin-Fixed, Paraffin-Embedded Sample-Based Companion Diagnostic for Personalized Treatment of the BRAF-Mutation-Like Subtype of Colorectal Cancers. <i>High-Throughput</i> , 2017, 6, 16. | 4.4 | 3 |
| 14 | The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting. <i>Breast Cancer Research</i> , 2017, 19, 99. | 2.2 | 58 |
| 15 | 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 717-729. | 13.9 | 1,427 |
| 16 | Prognostic Value of MammaPrint [®] in Invasive Lobular Breast Cancer. <i>Biomarker Insights</i> , 2016, 11, BMI.S38435. | 1.0 | 31 |
| 17 | Equivalence of MammaPrint array types in clinical trials and diagnostics. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 279-287. | 1.1 | 57 |
| 18 | Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 463-469. | 1.1 | 19 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Neoadjuvant tamoxifen synchronizes ER α binding and gene expression profiles related to outcome and proliferation. <i>Oncotarget</i> , 2016, 7, 33901-33918. | 0.8 | 13 |
| 20 | High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 707 Oncology, 2014, 25, 816-823. | 0.6 | 50 |
| 21 | MammaPrint Molecular Diagnostics on Formalin-Fixed, Paraffin-Embedded Tissue. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 190-197. | 1.2 | 90 |
| 22 | Additional prognostic value of the 70-gene signature (MammaPrint $\text{\textcircled{R}}$) among breast cancer patients with 4 \times 9 positive lymph nodes. <i>Breast</i> , 2013, 22, 682-690. | 0.9 | 47 |
| 23 | Performance characteristics of the MammaPrint $\text{\textcircled{R}}$ breast cancer diagnostic gene signature. <i>Personalized Medicine</i> , 2013, 10, 801-811. | 0.8 | 23 |
| 24 | Independent Validation of a Prognostic Genomic Signature (ColoPrint) for Patients With Stage II Colon Cancer. <i>Annals of Surgery</i> , 2013, 257, 1053-1058. | 2.1 | 102 |
| 25 | A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 37-47. | 1.1 | 121 |
| 26 | Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 17-24. | 0.8 | 487 |
| 27 | Impact of mammographic screening on the detection of good and poor prognosis breast cancers. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 725-734. | 1.1 | 76 |
| 28 | Comparison of MammaPrint and TargetPrint results with clinical parameters in German patients with early stage breast cancer. <i>International Journal of Molecular Medicine</i> , 2010, 26, 837-43. | 1.8 | 21 |
| 29 | The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 551-558. | 1.1 | 220 |
| 30 | Clinical Utility of the 70-gene MammaPrint Profile in a Japanese Population. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 508-512. | 0.6 | 35 |
| 31 | Biological Functions of the Genes in the MammaPrint Breast Cancer Profile Reflect the Hallmarks of Cancer. <i>Biomarker Insights</i> , 2010, 5, BML56184. | 1.0 | 103 |
| 32 | The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. <i>Annals of Oncology</i> , 2010, 21, 717-722. | 0.6 | 129 |
| 33 | MammaPrint $\text{\textcircled{R}}$ Translating Research into a Diagnostic Test. , 2010, , 165-184. | | 3 |
| 34 | Microarray-Based Determination of Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Status in Breast Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 7003-7011. | 3.2 | 87 |
| 35 | Gene expression profiling: Decoding breast cancer. <i>Surgical Oncology</i> , 2009, 18, 366-378. | 0.8 | 27 |
| 36 | Implementation of a novel microarray-based diagnostic test for cancer of unknown primary. <i>International Journal of Cancer</i> , 2009, 125, 1390-1397. | 2.3 | 45 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1â€³ positive lymph nodes in an independent validation study. Breast Cancer Research and Treatment, 2009, 116, 295-302. | 1.1 | 260 |
| 38 | Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Research and Treatment, 2009, 117, 483-495. | 1.1 | 154 |
| 39 | Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen. Breast Cancer Research and Treatment, 2009, 113, 275-283. | 1.1 | 56 |
| 40 | A gene expression profile for detection of sufficient tumour cells in breast tumour tissue: microarray diagnosis eligibility. BMC Medical Genomics, 2009, 2, 52. | 0.7 | 11 |
| 41 | PRAME expression and clinical outcome of breast cancer. British Journal of Cancer, 2008, 99, 398-403. | 2.9 | 90 |
| 42 | Gene Expression Profiling to Identify the Histogenetic Origin of Metastatic Adenocarcinomas of Unknown Primary. Journal of Clinical Oncology, 2008, 26, 4435-4441. | 0.8 | 176 |
| 43 | Analysis of the MammaPrint Breast Cancer Assay in a Predominantly Postmenopausal Cohort. Clinical Cancer Research, 2008, 14, 2988-2993. | 3.2 | 140 |
| 44 | Gene-Expression and Immunohistochemical Study of Specific T-Cell Subsets and Accessory Cell Types in the Transformation and Prognosis of Follicular Lymphoma. Journal of Clinical Oncology, 2007, 25, 390-398. | 0.8 | 221 |
| 45 | Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncology, The, 2007, 8, 1079-1087. | 5.1 | 268 |
| 46 | Robust interlaboratory reproducibility of a gene expression signature measurement consistent with the needs of a new generation of diagnostic tools. BMC Genomics, 2007, 8, 148. | 1.2 | 46 |
| 47 | Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics, 2006, 7, 278. | 1.2 | 429 |
| 48 | Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer. Journal of the National Cancer Institute, 2006, 98, 1183-1192. | 3.0 | 1,128 |
| 49 | Mechanisms and Effects of Loss of Human Leukocyte Antigen Class II Expression in Immune-Privileged Site-Associated B-Cell Lymphoma. Clinical Cancer Research, 2006, 12, 2698-2705. | 3.2 | 71 |
| 50 | Gene Expression Profiles of Primary Breast Carcinomas from Patients at High Risk for Local Recurrence after Breast-Conserving Therapy. Clinical Cancer Research, 2006, 12, 5705-5712. | 3.2 | 56 |
| 51 | Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood, 2005, 105, 301-307. | 0.6 | 208 |
| 52 | No common denominator for breast cancer lymph node metastasis. British Journal of Cancer, 2005, 93, 924-932. | 2.9 | 82 |
| 53 | Molecular Portraits and 70-Gene Prognosis Signature Are Preserved throughout the Metastatic Process of Breast Cancer. Cancer Research, 2005, 65, 9155-9158. | 0.4 | 302 |
| 54 | Gene expression profiles of primary breast tumors maintained in distant metastases. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 15901-15905. | 3.3 | 404 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Very late relapse in diffuse large B-cell lymphoma represents clonally related disease and is marked by germinal center cell features. <i>Blood</i> , 2003, 102, 324-327. | 0.6 | 40 |
| 56 | A Gene-Expression Signature as a Predictor of Survival in Breast Cancer. <i>New England Journal of Medicine</i> , 2002, 347, 1999-2009. | 13.9 | 5,759 |
| 57 | B-cell "autonomous somatic mutation deficit following bone marrow transplant. <i>Blood</i> , 2000, 96, 1064-1069. | 0.6 | 28 |
| 58 | B-cell "autonomous somatic mutation deficit following bone marrow transplant. <i>Blood</i> , 2000, 96, 1064-1069. | 0.6 | 6 |
| 59 | Human B cells accumulate immunoglobulin V gene somatic mutations in a cell contact-dependent manner in cultures supported by activated T cells but not in cultures supported by CD40 ligand. <i>Clinical and Experimental Immunology</i> , 1999, 116, 441-448. | 1.1 | 7 |
| 60 | Motif-specific probes identify individual genes and detect somatic mutations. <i>Molecular Immunology</i> , 1999, 36, 599-610. | 1.0 | 4 |
| 61 | Analysis of rearranged immunoglobulin heavy chain variable region genes obtained from a bone marrow transplant (BMT) recipient. <i>Clinical and Experimental Immunology</i> , 1997, 107, 372-380. | 1.1 | 10 |
| 62 | Non-stochastic utilization of Ig V region genes in unselected human peripheral B cells. <i>Molecular Immunology</i> , 1996, 33, 553-560. | 1.0 | 65 |
| 63 | VH repertoire in human B lymphocytes stimulated by CD40 ligand and IL-4: Evidence for positive and negative selection mechanisms coupled to CD40 activation. <i>Molecular Immunology</i> , 1996, 33, 1369-1376. | 1.0 | 7 |
| 64 | Polymorphism and Utilization of Human V _H Genes ^a . <i>Annals of the New York Academy of Sciences</i> , 1995, 764, 50-61. | 1.8 | 51 |
| 65 | Anomalous Diversification of the Antibody Repertoire following Bone Marrow Transplantation ^a . <i>Annals of the New York Academy of Sciences</i> , 1995, 764, 312-314. | 1.8 | 5 |